Summary media release information
Prostate cancer is the most common cancer affecting Australian men with almost 20,000 new cases diagnosed in 2009. Annually, over 3,000 men die of the disease.
To improve health outcomes for men, NHMRC has drafted a resource that will help health practitioners discuss the potential benefits and harms of a Prostate Specific Antigen (PSA) test with their patients.
NHMRC is now inviting public comments on the draft, particularly from health practitioners who care for men who are concerned about prostate cancer but who are not experiencing any symptoms of the disease.
“The draft resource aims to provide balanced, evidence-based information for health practitioners to support their discussions with men and their families,” NHMRC CEO Professor Warwick Anderson said.
“This resource is to help all men to be fully informed before deciding whether or not to have a PSA test to detect prostate cancer, equipped with a sound understanding of the possible effects of follow-up investigations and treatments.”
The draft resource was developed by a multidisciplinary expert advisory group with broad representation from disciplines including general practice, medical oncology, urology, pathology, public health, epidemiology, Aboriginal and rural health, and evidence-based practice. Consumers were also represented.
David Cooper, 0422 008 512
Page last updated on 22 July 2013